Strategies for Opioid Minimization Following Total Knee Arthroplasty: A Comprehensive Review

Abstract

The ongoing opioid epidemic has prompted a reexamination of perioperative pain management, especially in total knee arthroplasty (TKA)—a procedure known for its high amount of postoperative pain and historical reliance on opioids. Among strategies for opioid-naïve patients, three broad approaches have emerged: Quantity limitation, dynamic reassessment-based prescribing, and tiered, multimodal pain regimens. While limiting prescription size and scheduling timely follow-ups remain important tools, perhaps an important approach to consider is a tiered, multimodal pain management regimen. This strategy begins with baseline administration of non-opioid agents such as acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and gabapentinoids, escalating only as needed to tramadol and, if necessary, stronger opioids. Preoperative cryoneurolysis, intraoperative regional nerve blocks, and long-acting local anesthetics further enhance this regimen's ability to minimize opioid exposure. These clinical gains are now reinforced by the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, which provides separate Medicare reimbursement for select non-opioid pain treatments beginning in 2025, helping to eliminate financial barriers to adoption of these measures. In addition, real-world data—including results from the Innovations in Genicular Outcomes Research (iGOR) registry—have demonstrated the effectiveness of these techniques in reducing opioid use and improving functional and quality-of-life outcomes following TKA. Together, this convergence of clinical strategy, supportive policy, and data infrastructure provides a scalable and sustainable framework for advancing opioid stewardship in orthopaedic surgery without compromising patient comfort or recovery.

Keywords

perioperative pain management - total knee arthroplasty - multimodal anesthesia - non-operative management - cryoneurolysis - multicenter registry

Publication History

Received: 21 August 2025

Accepted: 23 December 2025

Accepted Manuscript online:
26 December 2025

Article published online:
20 January 2026

• References

• 1 Slater RR, Beverley L. The opioid epidemic in America: Pandemic impacts. J Am Acad Orthop Surg 2022; 30 (20) e1302-e1310
• 2 Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic opioid use after surgery: Implications for perioperative management in the face of the opioid epidemic. Anesth Analg 2017; 125 (05) 1733-1740
• 3 Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care 2016; 54 (10) 901-906
• 4 Singh GK, Kim Jr IE, Girmay M. et al. Opioid epidemic in the United States: Empirical trends, and a literature review of social determinants and epidemiological, pain management, and treatment patterns. Int J MCH AIDS 2019; 8 (02) 89-100
• 5 Irvine MA, Oller D, Boggis J. et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: A modelling study. Lancet Public Health 2022; 7 (03) e210-e218
• 6 Waljee JF, Gunaseelan V, Bicket MC, Brummett CM, Chua KP. Safety and distribution of opioid prescribing by U.S. surgeons. Ann Surg 2023; 277 (06) 944-951
• 7 Brummett CM, Waljee JF, Goesling J. et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg 2017; 152 (06) e170504
• 8 Roberts M, Brodribb W, Mitchell G. Reducing the pain: A systematic review of postdischarge analgesia following elective orthopedic surgery. Pain Med 2012; 13 (05) 711-727
• 9 Chung BC, Bouz GJ, Mayfield CK. et al. Dose-dependent early postoperative opioid use is associated with periprosthetic joint infection and other complications in primary TJA. J Bone Joint Surg Am 2021; 103 (16) 1531-1542
• 10 Howard R, Fry B, Gunaseelan V. et al. Association of opioid prescribing with opioid consumption after surgery in Michigan. JAMA Surg 2019; 154 (01) e184234-e184234
• 11 Howard R, Brown CS, Lai YL. et al. Postoperative opioid prescribing and new persistent opioid use: The risk of excessive prescribing. Ann Surg 2023; 277 (06) e1225-e1231
• 12 Danoff JR, Goel R, Sutton R, Maltenfort MG, Austin MS. How much pain is significant? Defining the minimal clinically important difference for the visual analog scale for pain after total joint arthroplasty. J Arthroplasty 2018; 33 (7S): S71 , 75.e2
• 13 Brody JE. A Year With My New Knees: Much Pain but Much Gain. The New York Times. December 20, 2005. Accessed March 25, 2025 at: https://www.nytimes.com/2005/12/20/health/a-year-with-my-new-knees-much-pain-but-much-gain.html
• 14 Elmallah RK, Cherian JJ, Pierce TP, Jauregui JJ, Harwin SF, Mont MA. New and common perioperative pain management techniques in total knee arthroplasty. J Knee Surg 2016; 29 (02) 169-178
• 15 Zywiel MG, Stroh DA, Lee SY, Bonutti PM, Mont MA. Chronic opioid use prior to total knee arthroplasty. J Bone Joint Surg Am 2011; 93 (21) 1988-1993
• 16 Larach DB, Hah JM, Brummett CM. Perioperative opioids, the opioid crisis, and the anesthesiologist. Anesthesiology 2022; 136 (04) 594-608
• 17 Karlsen APH, Wetterslev M, Hansen SE, Hansen MS, Mathiesen O, Dahl JB. Postoperative pain treatment after total knee arthroplasty: A systematic review. PLoS ONE 2017; 12 (03) e0173107
• 18 Politzer CS, Kildow BJ, Goltz DE, Green CL, Bolognesi MP, Seyler TM. Trends in opioid utilization before and after total knee arthroplasty. J Arthroplasty 2018; 33 (7S): S147-S153.e1
• 19 Gaffney CJ, Pelt CE, Gililland JM, Peters CL. Perioperative pain management in hip and knee arthroplasty. Orthop Clin North Am 2017; 48 (04) 407-419
• 20 Franzoni S, Rossi SMP, Cassinadri A, Sangaletti R, Benazzo F. Perioperative pain management in total knee arthroplasty: A narrative review of current multimodal analgesia protocols. Appl Sci (Basel) 2023; 13: 3798
• 21 van Deventer L, Bronstone A, Leonardi C, Bennett M, Yager P, Dasa V. A modern multimodal pain protocol eliminates the need for opioids for most patients following total knee arthroplasty: Results from a retrospective comparative cohort study. J Exp Orthop 2023; 10 (01) 20
• 22 Dave CV, Patorno E, Franklin JM. et al. Impact of state laws restricting opioid duration on characteristics of new opioid prescriptions. J Gen Intern Med 2019; 34 (11) 2339-2341
• 23 Agarwal S, Bryan JD, Hu HM. et al. Association of state opioid duration limits with postoperative opioid prescribing. JAMA Netw Open 2019; 2 (12) e1918361
• 24 Pacira. What is Iovera?. Accessed April 15, 2024 at: https://www.ioverapro.com/what-is-iovera
• 25 Mont MA, Lin JH, Spitzer AI. et al. Cryoneurolysis associated with improved pain, function, and sleep in patients following total knee arthroplasty: Use of a new real-world registry. J Arthroplasty 2025; 40 (01) 92-101.e3
• 26 Concoff AL, Lin JH, Spitzer AI. et al. Association of knee osteoarthritis treatment types, patient characteristics, and medical history with subsequent risk for total knee arthroplasty: Data from a new real-world registry. Arthroplast Today 2025; 32: 101643
• 27 McHenry P, Mellor J. Medicare hospital payment adjustments and nursing wages. Int J Health Econ Manag 2018; 18 (02) 169-196
• 28 Microsite NOPAIN. Accessed March 27, 2025 at: https://www.nopainpact.com/
• 29 AAHKS. Reminder: NOPAIN Act Now in Effect. Accessed March 27, 2025 at: https://www.aahks.org/wp-content/uploads/2025/01/AAHKS-Summary-No-Pain-Act-Implementation-01.07.25-1.pdf
• 30 U.S. Food and Drug Administration. FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain. Accessed March 27, 2025 at: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain
• 31 Mont MA, Lin JH, Spitzer AI. et al. Improved pain and function with triamcinolone acetonide extended-release and cryoneurolysis for knee osteoarthritis: Use of a new real-world registry. J Arthroplasty 2025; 40 (02) 328-338.e2
• 32 Mont MA, Lin JH, Spitzer AI. et al. Improved sleep associated with triamcinolone acetonide extended-release injections for knee osteoarthritis: Use of a new real-world registry. Arthroplast Today 2025; 32: 101655
• 33 ClinicalTrials.gov. Innovations in Genicular Outcomes Registry (iGOR). Accessed March 8, 2024 at: https://classic.clinicaltrials.gov/ct2/show/NCT05495334
• 34 Dasa V, Mihalko W, Rivadeneyra A. et al. Innovations in Genicular Outcomes Registry (IGOR): Protocol for a real-world registry study of treatments for knee osteoarthritis. Ther Adv Musculoskelet Dis 2024; 16: X241304193
• 35 Burn E, Weaver J, Morales D. et al. Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: A population-based network study. Lancet Rheumatol 2019; 1 (04) e229-e236
• 36 Hak DJ, Mackowiak JI, Irwin DE, Aldridge ML, Mack CD. Real-world evidence: A review of real-world data sources used in orthopaedic research. J Orthop Trauma 2021; 35 (Suppl. 01) S6-S12
• 37 Asche CV, Dagenais S, Kang A, Ren J, Maurer BT. Impact of treatment with liposomal bupivacaine on hospital costs, length of stay, and discharge status in patients undergoing total knee arthroplasty at high-use institutions. J Med Econ 2019; 22 (01) 85-94